Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Publication year range
1.
Sci Rep ; 9(1): 3978, 2019 03 08.
Article in English | MEDLINE | ID: mdl-30850691

ABSTRACT

Animals that communicate using sound are found throughout the animal kingdom. Interestingly, in contrast to human vocal learning, most animals can produce species-specific patterns of vocalization without learning them from their parents. This phenomenon is called innate vocalization. The underlying molecular basis of both vocal learning in humans and innate vocalization in animals remains unknown. The crowing of a rooster is also innately controlled, and the upstream center is thought to be localized in the nucleus intercollicularis (ICo) of the midbrain. Here, we show that the cholecystokinin B receptor (CCKBR) is a regulatory gene involved in inducing crowing in roosters. Crowing is known to be a testosterone (T)-dependent behavior, and it follows that roosters crow but not hens. Similarly, T-administration induces chicks to crow. By using RNA-sequencing to compare gene expression in the ICo between the two comparison groups that either crow or do not crow, we found that CCKBR expression was upregulated in T-containing groups. The expression of CCKBR and its ligand, cholecystokinin (CCK), a neurotransmitter, was observed in the ICo. We also showed that crowing was induced by intracerebroventricular administration of an agonist specific for CCKBR. Our findings therefore suggest that the CCK system induces innate vocalization in roosters.


Subject(s)
Chickens/metabolism , Chickens/physiology , Cholecystokinin/metabolism , Crows/metabolism , Crows/physiology , Animals , Behavior, Animal/physiology , Gene Expression/physiology , Male , Neurotransmitter Agents/metabolism , Receptor, Cholecystokinin B/metabolism , Sound , Testosterone/metabolism , Up-Regulation/physiology , Vocalization, Animal/physiology
2.
Chem Pharm Bull (Tokyo) ; 66(10): 959-966, 2018.
Article in English | MEDLINE | ID: mdl-30270242

ABSTRACT

Although many in silico models were reported to predict the skin permeation of drugs from aqueous solutions, few studies were founded on the in silico estimation models for the skin permeation of drugs from neat oil formulations and o/w emulsions. In the present study, the cumulative amount of a model lipophilic drug, flurbiprofen (FP), that permeated through skin was determined from 12 different kinds of ester oils (Qoil) and an in silico model was developed for predicting the skin permeation of FP from these ester oils. Thus, the obtained Qoil values were well predicted with the FP solubility in the oils (Soil), the amount of FP uptake into the stratum corneum (SCoil) and molecular descriptors of dipolarity/polarizability (π2H) and molecular density. This model suggests that the thermodynamic activities of FP both in the formulations and skin are the key factors for predicting the skin permeation of FP from the ester oils. In addition, a high linear relationship was observed in the double-logarithm plots between the Qoil and the cumulative amount of FP permeated through skin from 20% ester oil in water emulsion (Qemul20%). Furthermore, the skin permeations of FP from 5 and 10% ester oil in water emulsions, Qemul5% and Qemul10%, respectively, were also predicted by the horizontal translation of the y-axis intercept of the liner equation for the relation between the Qoil and Qemul20%. These prediction methods must be helpful for designing topical oily and/or o/w emulsion formulations having suitable and high skin permeation rate of lipophilic drugs.


Subject(s)
Esters/chemistry , Flurbiprofen/metabolism , Plant Oils/chemistry , Skin/metabolism , Animals , Ear , Emulsions/chemistry , Flurbiprofen/chemistry , Skin Absorption , Solubility , Swine , Water/chemistry
3.
J Cosmet Sci ; 66(5): 295-303, 2015.
Article in English | MEDLINE | ID: mdl-26753433

ABSTRACT

Skin care with moisturizers to compensate for dry skin and decreased barrier function, and to prevent recurrence of inflammation is thought to be very important for management of atopic dermatitis. However, many patients cannot continue the use of moisturizing medications because of unpleasantness. Cosmetics may be able to compensate for such deficiencies. To evaluate the usefulness of cosmetics in maintenance of the skin in remission, we conducted a clinical trial using moisturizing cosmetics of a phospholipid preparation that showed good moisture-retaining effect in dry skin. The utility of moisturizing cosmetics was evaluated by skin findings, subjective symptoms, adverse events, moisture content of the stratum corneum, transepidermal water loss (TEWL), and a questionnaire on feel of use in comparison with a heparinoid preparation as a control product. Degree of improvement in skin findings, dryness and desquamation score, pruritus score, TEWL, and moisture content were nearly the same as with the control product. The result indicated that the moisturizing cosmetic was of equivalent effect compared with the heparinoid control preparation.


Subject(s)
Dermatitis, Atopic/drug therapy , Emollients/therapeutic use , Skin/physiopathology , Adult , Dermatitis, Atopic/physiopathology , Female , Humans , Male , Middle Aged , Single-Blind Method , Young Adult
4.
Mol Cancer Res ; 11(7): 689-98, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23594796

ABSTRACT

Oncogenic c-Myc plays a critical role in cell proliferation, apoptosis, and tumorigenesis, but the precise mechanisms that drive this activity remain largely unknown. P27Kip1 (CDKN1B) arrests cells in G1, and SAP155 (SF3B1), a subunit of the essential splicing factor 3b (SF3b) subcomplex of the spliceosome, is required for proper P27 pre-mRNA splicing. FUSE-binding protein-interacting repressor (FIR), a splicing variant of PUF60 lacking exon5, is a c-Myc transcriptional target that suppresses the DNA helicase p89 (ERCC3) and is alternatively spliced in colorectal cancer lacking the transcriptional repression domain within exon 2 (FIRΔexon2). FIR and FIRΔexon2 form a homo- or hetero-dimer that complexes with SAP155. Our study indicates that the FIR/FIRΔexon2/SAP155 interaction bridges c-Myc and P27 expression. Knockdown of FIR/FIRΔexon2 or SAP155 reduced p27 expression, inhibited its pre-mRNA splicing, and reduced CDK2/Cyclin E expression. Moreover, spliceostatin A, a natural SF3b inhibitor, markedly inhibited P27 expression by disrupting its pre-mRNA splicing and reduced CDK2/Cyclin E expression. The expression of P89, another FIR target, was increased in excised human colorectal cancer tissues. Knockdown of FIR reduced P89; however, the effects on P27 and P89 expression are not simply or directly related to altered FIR expression levels, indicating that the mechanical or physical interaction of the SAP155/FIR/FIRΔexon2 complex is potentially essential for sustained expression of both P89 and P27. Together, the interaction between SAP155 and FIR/FIRΔexon2 not only integrates cell-cycle progression and c-Myc transcription by modifying P27 and P89 expression but also suggests that the interaction is a potential target for cancer screening and treatment.


Subject(s)
Cyclin-Dependent Kinase Inhibitor p27/metabolism , Phosphoproteins/metabolism , Proto-Oncogene Proteins c-myc/metabolism , RNA-Binding Proteins/metabolism , Repressor Proteins/metabolism , Ribonucleoprotein, U2 Small Nuclear/metabolism , Alternative Splicing/genetics , Cell Line, Tumor , Cell Proliferation/drug effects , Colonic Neoplasms/metabolism , Colonic Neoplasms/pathology , Cyclin E/metabolism , Cyclin-Dependent Kinase Inhibitor p27/genetics , DNA Helicases/metabolism , DNA-Binding Proteins/metabolism , G1 Phase Cell Cycle Checkpoints/drug effects , Gene Knockdown Techniques , Humans , Models, Biological , Protein Binding/drug effects , Pyrans/pharmacology , RNA Precursors/genetics , RNA Precursors/metabolism , RNA Splicing Factors , RNA, Small Interfering/metabolism , RNA-Binding Proteins/genetics , Repressor Proteins/genetics , Spiro Compounds/pharmacology , Transcription Factor TFIIH/metabolism
5.
Cancer Sci ; 104(2): 149-56, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23113893

ABSTRACT

The c-myc transcriptional suppressor, far-upstream element (FUSE)-binding protein (FBP)-interacting repressor (FIR), is alternatively spliced in colorectal cancer tissue (Matsushita et al., Cancer Res 2006). Recently, the knockdown of SAP155 pre-mRNA-splicing factor, a subunit of SF3b, was reported to disturb FIR pre-mRNA splicing and yield FIRΔexon2, an exon 2-spliced variant of FIR, which lacks c-myc repression activity. In the present study, novel splicing variants of FIR, Δ3 and Δ4, were also generated by SAP155 siRNA, and these variants were found to be activated in human colorectal cancer tissue. Furthermore, the expression levels of FIR variant mRNA were examined in the peripheral blood of colorectal cancer patients and healthy volunteers to assess its potency for tumor detection. As expected, circulating FIR variant mRNA in the peripheral blood of cancer patients were significantly overexpressed compared to that in healthy volunteers. In particular, the area under the receiving operating characteristic curve of FIR, FIRΔexon2 or FIRΔexon2/FIR, was greater than those of conventional carcinoembryonic antigen or carbohydrate antigen 19-9. In addition, FIRΔexon2 or FIR mRNA expression in the peripheral blood was significantly reduced after operative removal of colorectal tumors. Thus, circulating FIR and FIRΔexon2 mRNA are potential novel screening markers for colorectal cancer testing with conventional carcinoembryonic antigen and or carbohydrate antigen 19-9. Taken together, our results indicate that overexpression of FIR and its splicing variants in colorectal cancer directs feed-forward or addicted circuit c-myc transcriptional activation. Clinical implications for colorectal cancers of novel FIR splicing variants are also discussed in the present paper.


Subject(s)
Colonic Neoplasms/genetics , Guanine Nucleotide Exchange Factors/genetics , Phosphoproteins/genetics , Proto-Oncogene Proteins c-myc/genetics , Ribonucleoprotein, U2 Small Nuclear/genetics , Alternative Splicing , Animals , Antigens, Tumor-Associated, Carbohydrate/genetics , Antigens, Tumor-Associated, Carbohydrate/metabolism , Biomarkers, Tumor , COS Cells , Cell Line, Tumor , Chlorocebus aethiops , Colonic Neoplasms/metabolism , Exons/genetics , Genes, Tumor Suppressor , Guanine Nucleotide Exchange Factors/metabolism , HCT116 Cells , HeLa Cells , Humans , Phosphoproteins/metabolism , Protein Isoforms , Proto-Oncogene Proteins c-myc/metabolism , RNA Precursors/genetics , RNA Precursors/metabolism , RNA Splicing , RNA Splicing Factors , RNA, Messenger/genetics , RNA, Small Interfering/genetics , Rho Guanine Nucleotide Exchange Factors , Ribonucleoprotein, U2 Small Nuclear/metabolism , Transcription, Genetic , Transcriptional Activation
6.
Mol Cancer Res ; 10(6): 787-99, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22496461

ABSTRACT

The Far UpStream Element (FUSE)-binding protein-interacting repressor (FIR), a c-myc transcriptional suppressor, is alternatively spliced removing the transcriptional repression domain within exon 2 (FIRΔexon2) in colorectal cancers. SAP155 is a subunit of the essential splicing factor 3b (SF3b) subcomplex in the spliceosome. This study aims to study the significance of the FIR-SAP155 interaction for the coordination of c-myc transcription, pre-mRNA splicing, and c-Myc protein modification, as well as to interrogate FIRΔexon2 for other functions relating to altered FIR pre-mRNA splicing. Knockdown of SAP155 or FIR was used to investigate their reciprocal influence on each other and on c-myc transcription, pre-mRNA splicing, and protein expression. Pull down from HeLa cell nuclear extracts revealed the association of FIR, FIRΔexon2, and SF3b subunits. FIR and FIRΔexon2 were coimmunoprecipitated with SAP155. FIR and FIRΔexon2 adenovirus vector (Ad-FIR and Ad-FIRΔexon2, respectively) were prepared to test for their influence on c-myc expression. FIR, SAP155, SAP130, and c-myc were coordinately upregulated in human colorectal cancer. These results reveal that SAP155 and FIR/FIRΔexon2 form a complex and are mutually upregulating. Ad-FIRΔexon2 antagonized Ad-FIR transcriptional repression of c-myc in HeLa cells. Because FIRΔexon2 still carries RRM1 and RRM2 and binding activity to FUSE, it is able to displace repression competent FIR from FUSE in electrophoretic mobility shift assays, thus thwarting FIR-mediated transcriptional repression by FUSE. Thus aberrant FIRΔexon2 production in turn sustained c-Myc expression. In conclusion, altered FIR and c-myc pre-mRNA splicing, in addition to c-Myc expression by augmented FIR/FIRΔexon2-SAP155 complex, potentially contribute to colorectal cancer development.


Subject(s)
Alternative Splicing , Phosphoproteins/metabolism , Proto-Oncogene Proteins c-myc/genetics , RNA-Binding Proteins/genetics , Repressor Proteins/genetics , Ribonucleoprotein, U2 Small Nuclear/metabolism , Amino Acid Sequence , Base Sequence , Blotting, Western , Colorectal Neoplasms/genetics , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/pathology , Exons/genetics , HCT116 Cells , HEK293 Cells , HeLa Cells , Humans , Introns/genetics , Molecular Sequence Data , Mutation , Phosphoproteins/genetics , Protein Binding , Proto-Oncogene Proteins c-myc/metabolism , RNA Interference , RNA Precursors/genetics , RNA Precursors/metabolism , RNA Splicing Factors , RNA-Binding Proteins/metabolism , Repressor Proteins/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Ribonucleoprotein, U2 Small Nuclear/genetics , Transcription, Genetic
7.
Am J Dermatopathol ; 33(4): 397-9, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21124205

ABSTRACT

Blastomycosis-like pyoderma (BLP) is a type of chronic pyoderma characterized histologically by specific epidermal changes namely: pseudoepitheliomatous hyperplasia and intraepithelial abscesses. These epidermal changes are also seen in blastomycosis (referred to as deep dermatophytosis in North America). Here, we describe the case of a 53-year-old male with prurigo nodularis, diabetes, and chronic lymphocytic leukemia who presented with multiple yellowish-red colored papules that coalesced to form a vegetating plaque. In addition to the typical features of BLP, spores with budding were seen histopathologically in a biopsy specimen. Cultures of a skin specimen grew Staphylococcus epidermidis and Trichophyton rubrum. Antibiotic therapy was effective but failed to eliminate the lesion until antifungal therapy using terbinafine was administered concurrently. Past reports suggest that BLP is mainly caused by bacterial infection, but our case suggests that fungal infection can also be involved as the causative organism in BLP.


Subject(s)
Blastomycosis/pathology , Dermatomycoses/pathology , Pyoderma/pathology , Skin Diseases, Bacterial/pathology , Staphylococcal Infections/pathology , Tinea/pathology , Anti-Bacterial Agents/therapeutic use , Antifungal Agents/therapeutic use , Blastomycosis/complications , Blastomycosis/microbiology , Dermatomycoses/complications , Dermatomycoses/drug therapy , Dermatomycoses/microbiology , Humans , Immunocompromised Host , Male , Middle Aged , Pyoderma/complications , Pyoderma/microbiology , Skin Diseases, Bacterial/complications , Skin Diseases, Bacterial/drug therapy , Skin Diseases, Bacterial/microbiology , Staphylococcal Infections/complications , Staphylococcal Infections/drug therapy , Staphylococcal Infections/microbiology , Staphylococcus epidermidis/isolation & purification , Tinea/complications , Tinea/drug therapy , Tinea/microbiology , Treatment Outcome , Trichophyton/isolation & purification
8.
Rinsho Byori ; 57(12): 1151-8, 2009 Dec.
Article in Japanese | MEDLINE | ID: mdl-20077813

ABSTRACT

Development of useful biomarkers is pivotal for prediction of micro-metastasis, recurrence probability and/or prognosis of the patients. Recent studies have revealed that cancer-specific alternative splicing can be valuable for cancer cell detection. Among them, FUSE-binding protein-interacting repressor, FIR, has been reported to repress c-myc transcription and its exon2-spliced variant, FIRDelta(exon)2, is unable to repress c-myc by competing with authentic FIR in vivo and in vitro. Moreover FIRDelta(exon)2 was frequently discovered in human primary colorectal cancers, but not in the adjacent normal tissues, indicating its cancer-related expression. Thus, the expression level of FIRDelta(exon)2 mRNA in the colorectal cancer tissues as tumor marker candidates is examined. Further, to determine the interacting proteins, FIR-flag or FIRDelta(exon)2-flag stably expressing HeLa cells have been established by G418 selection and nuclear proteins were co immunoprecipitated with flag-conjugated magnetic beads. Those co-immunoprecipitated proteins with FIR or FIRDelta(exon)2 are candidates of tumor makers. In addition, substances that interfers FIR mRNA splicing should be anti-cancer drugs. Together, FIR splicing variant, FIRDelta(exon)2 mRNA or proteins and its interacting proteins are applicable for novel screening tumor markers in colorectal cancer detection.


Subject(s)
Alternative Splicing , Biomarkers, Tumor/analysis , Biomarkers, Tumor/genetics , Carrier Proteins/analysis , Carrier Proteins/genetics , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/therapy , Genes, myc/genetics , DNA-Binding Proteins , Drug Screening Assays, Antitumor , Exons , HeLa Cells , Humans , Nuclear Proteins , RNA Splicing Factors , RNA, Messenger/genetics , RNA-Binding Proteins , Repressor Proteins , Transcription, Genetic , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...